Dermatomyositis and polymyositis (myositis): vizsgálatok itt: Kína
38 trials · From ClinicalTrials.gov, checked 2026. november 13.. Ask the study team whether a trial fits you.
- Korai 1. fázisTaking peopleAn Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases
- Where
- Shanghai
- Életkor
- 18 év to 70 év
- People
- 20
- Run by
- Shanghai Cell Therapy Group Co.,Ltd
See details and how to joinNCT07174843 - 3. fázisNot yet taking people in KínaA Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies
- Where
- Beijing, Chongqing, Dongguan, Guangzhou, Hefei, Luoyang, Nanchang, Nanjing, Shanghai, Wenzhou, Wuhan, Xi'an
- Életkor
- 18 év and over
- People
- 270 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07789015 · EU 2026-526365-24-00 - 1. fázisTaking peopleA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
- Where
- Beijing, Shanghai, Wuhan, Zhengzhou
- Életkor
- 18 év to 70 év
- People
- 72 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06916806 · EU 2024-519015-34-00 - 3. fázisCsak meghívásosA Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
- Where
- Beijing, Chengdu, Guangzhou, Nanjing, Shanghai, Shenyang, Zhengzhou
- Életkor
- 18 év and over
- People
- 240 worldwide
- Run by
- argenx
See details and how to joinNCT05979441 · EU 2022-502851-79-00 - 1/2. fázisTaking peopleSafety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
- Where
- Tianjin
- Életkor
- 18 év to 60 év
- People
- 27
- Run by
- Tianjin Medical University General Hospital
See details and how to joinNCT07022197 - 3. fázisTaking peopleA Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
- Where
- Beijing, Chongqing, Dongguan, Guangzhou, Hangzhou, Hengyang, Jining, Nanjing, Shanghai, Shijiazhuang, Wenzhou, Zhengzhou
- Életkor
- 18 év to 75 év
- People
- 240 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06455449 - Korai 1. fázisTaking peopleClinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases
- Where
- Beijing
- Életkor
- 18 év to 80 év
- People
- 10
- Run by
- Peking University Third Hospital
See details and how to joinNCT07301164 - 3. fázisTaking peopleA Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
- Where
- Beijing, Cangzhou, Changsha, Chengdu, Dongguan, Guangzhou, Hangzhou, Hefei, Kunming, Nanchang, Nanjing, Shanghai, Tianjin
- Életkor
- 18 év and over
- People
- 318 worldwide
- Run by
- Pfizer
See details and how to joinNCT05895786 · EU 2022-502739-20-00 - 3. fázisTaking peopleA Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
- Where
- Beijing, Hefei, Kunming, Nanchang, Shanghai
- Életkor
- 18 év and over
- People
- 211 worldwide
- Run by
- Pfizer
See details and how to joinNCT06698796 · EU 2024-514648-10-00 - No phaseTaking peopleBiomarkers in Autoimmune Disease of Nervous System
- Where
- Wuhan
- Életkor
- 18 év and over
- People
- 50 000
- Run by
- Tongji Hospital
See details and how to joinNCT06502015 - 1. fázisTaking peopleBCMA-CD19 cCAR-T for the Treatment of Refractory Inflammatory Myopathy
- Where
- Chengdu
- Életkor
- 18 év to 60 év
- People
- 10
- Run by
- iCell Gene Therapeutics
See details and how to joinNCT07715136 - Korai 1. fázisNot yet taking people in KínaCD19/BCMA-Targeted Universal CAR-T Cell Injection for the Treatment of Autoimmune Diseases
- Where
- Shanghai
- Életkor
- 18 év to 70 év
- People
- 30
- Run by
- Nanjing Bioheng Biotech Co., Ltd.
See details and how to joinNCT07596680 - Korai 1. fázisTaking peopleMTS109 in Patients With Refractory Autoimmune Diseases
- Where
- Shanghai
- Életkor
- 18 év to 65 év
- People
- 15
- Run by
- Shanghai Changzheng Hospital
See details and how to joinNCT07526350 - Korai 1. fázisNot yet taking people in KínaRD06-05 Universal CD19/BCMA CAR-T for Refractory Pediatric Autoimmune Diseases
- Where
- Hangzhou, Nanjing
- Életkor
- 5 év to 20 év
- People
- 30
- Run by
- The Children's Hospital of Zhejiang University School of Medicine
See details and how to joinNCT07674147 - 1. fázisTaking peopleSafety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
- Where
- Wuhan
- Életkor
- 18 év to 75 év
- People
- 6
- Run by
- Tongji Hospital
See details and how to joinNCT07526493 - No phaseTaking peopleExploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune Diseases
- Where
- Nanjing
- Életkor
- 18 év to 70 év
- People
- 72
- Run by
- The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT07558850 - Korai 1. fázisTaking peopleA Study of CC312 for Relapsed/Refractory Autoimmune Diseases
- Where
- Deyang
- Életkor
- 18 év to 65 év
- People
- 6
- Run by
- CytoCares Inc
See details and how to joinNCT07193810 - Korai 1. fázisTaking peopleClinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases
- Where
- Bengbu
- Életkor
- 18 év to 70 év
- People
- 20
- Run by
- Nanjing Bioheng Biotech Co., Ltd.
See details and how to joinNCT06548607 - 1. fázisNot yet taking people in KínaYTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases
- Where
- Shanghai
- Életkor
- 5 év to 18 év
- People
- 12
- Run by
- Children's Hospital of Fudan University
See details and how to joinNCT07439029 - 1. fázisTaking peopleA Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM)
- Where
- Bengbu, Changsha, Guangzhou, Nanchang, Xuzhou
- Életkor
- 18 év to 70 év
- People
- 38
- Run by
- Nanjing Legend Biotech Co.
See details and how to joinNCT07331272 - No phaseTaking peopleRCT of Tocilizumab for Anti-MDA5+DM
- Where
- Beijing
- Életkor
- 18 év to 65 év
- People
- 110
- Run by
- Peking Union Medical College Hospital
See details and how to joinNCT07377058 - No phaseNot yet taking people in KínaTongji NADs Cohort
- Where
- Wuhan
- Életkor
- 18 év to 80 év
- People
- 1550
- Run by
- Tongji Hospital
See details and how to joinNCT07333196 - 1. fázisTaking peopleCAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
- Where
- Tianjin
- Életkor
- 18 év and over
- People
- 12
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07315087 - Korai 1. fázisTaking peopleGC012F Injection in Refractory Idiopathic Inflammatory Myopathy
- Where
- Wuhan
- Életkor
- 18 év to 70 év
- People
- 12
- Run by
- Daishi Tian
See details and how to joinNCT07086404 - No phaseTaking peopleAnti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases
- Where
- Hangzhou
- Életkor
- 18 év to 65 év
- People
- 15
- Run by
- Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT06614270